Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting"). The special resolution approving t
Cannabis, Santé, Psychédéliques, Fournisseurs de services auxiliaires liés au cannabis
2026-05-13 9:12 AM EDT | Red Light Holland Corp.
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director. At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Pha
2026-05-13 8:00 AM EDT | BetterLife Pharma Inc.
RETRANSMISSION: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for ne
2026-05-13 8:00 AM EDT | DiagnosTear Technologies Inc.
BioHarvest Sciences Announces Successful Completion of Stage 1 Development of Saffron Composition for Nutraceutical and Culinary Applications
- CDMO program advances to Stage 2 of development agreement valued at $1.125 million -Advancement of sustainable solution for the production of saffron, one of the world's most valuable and health-promoting botanicals - In addition to future commercial manufacturing royalties, BioHarvest also holds a 25% ownership position in Saffron Composition Vancouver, British Colum
Biotechnologies, Pharmaceutique, Santé
2026-05-13 8:00 AM EDT | BioHarvest Sciences Inc.
Charlotte's Web First Quarter 2026 Financial Results
Louisville, Colorado--(Newsfile Corp. - May 13, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and the market leader in cannabidiol (CBD) hemp extract wellness products, today announced results for the quarter ended March 31, 2026. All amounts are expressed in U.S. dollars. TRANSACTION AND SUBSEQUENT EVENTS UPDATE Propose
2026-05-13 7:07 AM EDT | Charlotte's Web Holdings, Inc.
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc., is preparing for its official entry into the United States market. This expansion marks a pivotal milestone in the Company's North American growth strategy under its new leadership team. While the brand previously maintained a broader internatio
Technologies, Biotechnologies, Santé
2026-05-13 6:00 AM EDT | Restart Life Sciences Corp.
TelyRx Announces First Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced financial results for the first quarter ended March 31, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the First Quarter of 2026 Revenue increased to $19.4 million, compared to $14.3 million in Q
Soins de santé et hôpitaux, Santé
2026-05-12 5:57 PM EDT | TelyRx
PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news release dated April 22, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $1,000,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 13,600,000 units (e
Biotechnologies, Pharmaceutique, Santé
2026-05-12 5:02 PM EDT | PreveCeutical Medical Inc.
DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies, is pleased to announce that on May 12, 2026, it has entered into a definitive exclusive global license agreement for the commercialization of the CLARIFY eye imaging platform, A breakthrough technology enabling blood analysis through a simple eye scan, eliminating the need for ne
2026-05-12 4:05 PM EDT | DiagnosTear Technologies Inc.
TelyRx to Host First Quarter 2026 Financial Results Conference Call on Wednesday, May 13, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - May 12, 2026) - TelyRx Holdings Inc. (TSX: TELY) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its first quarter 2026 financial results on Wednesday, May 13, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its first quarter 2026 financial results for the period ended March 31, 2026, after market cl
Soins de santé et hôpitaux, Santé
2026-05-12 10:45 AM EDT | TelyRx
DIMERx Preclinical Data Confirms DMX-101 Non-Addictive Profile: No Reinforcement, No Dependence
San Francisco, California--(Newsfile Corp. - May 12, 2026) - DIMERx, Inc. ("DIMERx" or "the Company") is a clinical-stage biopharmaceutical company dedicated to addressing the public-health crisis of drug misuse and dependence, with a portfolio of first-
Biotechnologies, Pharmaceutique, Santé
2026-05-12 9:00 AM EDT | DIMERx INC.
CBD of Denver, Inc. Identifies Strategic Opportunities to Maximize Shareholder Value
Zurich, Switzerland--(Newsfile Corp. - May 12, 2026) - CBD of Denver Inc. (OTC Pink: CBDD) ("the Company") today announced that its management is actively pursuing potential strategic opportunities designed to position the Company for long-term growth and enhance value for its shareholders. Management is currently evaluating several prospective candidates, assets, and strategic initiatives that align with the Company's long-term vision and growth strategy. The Board of Directors believe
Cannabis, Santé, Extracteurs de cannabis, Producteurs de cannabis
2026-05-12 9:00 AM EDT | CBD of Denver Inc.
Functional Brands Inc. Announces Conversion Price Adjustment Agreement for Series C Preferred Stock
Lake Oswego, Oregon--(Newsfile Corp. - May 12, 2026) - Functional Brands Inc. (NASDAQ: MEHA), (the "Company"), a leading innovator in wellness and performance products, today announced that it has entered into a Conversion Price Reduction and Waiver Agreement with all holders of the Company's Series C Convertible Preferred Stock. Under the terms of the Agreement, the conversion price applicable to the Series C Preferred Stock during the Fixed Conversion Period has been modified to $0.16
Produits ménagers / de consommation / cosmétiques, Santé
2026-05-12 8:00 AM EDT | Functional Brands Inc.
BioHarvest Sciences Signs $1.2M CDMO Stage 2 Contract for the Development of a Rare Fragrance Using Its Proprietary Botanical Synthesis Platform
British Columbia and Rehovot, Israel--(Newsfile Corp. - May 12, 2026) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its CDMO division has s
Biotechnologies, Pharmaceutique, Santé
2026-05-12 7:30 AM EDT | BioHarvest Sciences Inc.
Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - May 12, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing tec
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-12 7:00 AM EDT | Phio Pharmaceuticals Corp.
Beckett's Closes US$500,000 5-Year 8% Convertible Debenture Financing
Ontario and Los Angeles, California--(Newsfile Corp. - May 11, 2026) - Beckett's Inc. (CSE: BKTS) ("Beckett's" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement of 5-year 8% secured convertible debentures of the Company (the "Debentures") for aggregate gross proceeds of US$500,000 (the "Financing"). No finder's fees, commissions or other compensation were paid in connection with the Financi
Aliments / boissons, Cannabis, Santé
2026-05-11 6:00 PM EDT | Becketts Inc.
TERSIS Technologies Appoints Steven R. Miller, Sr. as Senior Advisor - Global Business Development & Strategic Partnerships
Brooksville, Florida--(Newsfile Corp. - May 11, 2026) - Tersis Technologies, Inc. (OTCID: TERS), a company focused on acquiring and deploying technologies that convert waste streams into regenerative energy, valuable commodities, and sustainable infrastructure solutions, today announced the appointment of Steven R. Miller, Sr. as Senior Advisor - Global Business Development & Strategic Partnerships.
Agriculture, Énergie, Énergies de substitution, Santé
2026-05-11 10:45 AM EDT | Tersis Technologies Inc.
ADIA Nutrition Announces IRB Approval of All Four Clinical Studies and Registration of Kidney Health Study on ClinicalTrials.gov
Winter Park, Florida--(Newsfile Corp. - May 11, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a publicly traded company advancing regenerative medicine through its subsidiary Adia Med of Winter Park, LLC, today announced that all four of its planned clinical studies have received Institutional Review Board (IRB) approval. This milestone enables the continued execution and launch of human trials evaluating the safety and potential efficacy of the Company's proprietary AdiaVita™ stem cell a
Soins de santé et hôpitaux, Santé
2026-05-11 10:04 AM EDT | Adia Nutrition Inc.
Functional Brands Inc. Signs Binding Letter of Intent for the Acquisition of the Assets of BullionFX | Alchemy for $142.9 million
Lake Oswego, Oregon--(Newsfile Corp. - May 11, 2026) - Functional Brands Inc. (NASDAQ: MEHA) (the "Company"), a leading innovator in wellness and performance products, today announced it has executed a binding Letter of Intent ("LOI") to acquire the assets of BullionFX, including its core product Alchemy (collectively, the "BullionFX Assets"), in an all-stock transaction valued at approximately $142.9 million. The transaction contemplated by the LOI represents a strategic asset acquisi
Produits ménagers / de consommation / cosmétiques, Santé
2026-05-11 8:00 AM EDT | Functional Brands Inc.
Edison Issues Report on Omantel (OTEL)
London, United Kingdom--(Newsfile Corp. - May 11, 2026) - Edison issues report on Omantel (MSX: OTEL). Omantel is a leading integrated telecom operator in Oman with a strategic regional footprint through its stake in Zain, combining a stable domestic telecom base with exposure to broader MENA markets. The investment case is increasingly centred on its transition towards a more diversified digital infrastructure and technology platform, driven by the scaling of ICT and international whol
Services bancaires / financiers, Matériel informatique, Logiciels, Santé
2026-05-11 7:43 AM EDT | Edison Group